Dare Bioscience financials
$0.8150+8.67%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $187.5K | $152.5K | $1.0M | $2.3K | -$21.2K | $25.4K | — | $41.7K | $22.4K | $9.3K | $1.8M | $1.0M |
| Gross profit | -$132.3K | -$89.9K | $727.9K | $2.3K | -$21.2K | $25.4K | — | $41.7K | $22.4K | $9.3K | $1.8M | $1.0M |
| Gross margin | −70.6% | −58.9% | 71.1% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$3.0M | -$3.0M | -$1.5M | -$3.7M | -$3.8M | -$4.6M | — | -$4.7M | -$7.4M | -$6.0M | -$5.2M | -$8.4M |
| Net income | -$3.0M | -$3.0M | -$1.4M | -$3.6M | -$4.0M | -$4.4M | — | -$4.7M | $12.9M | -$6.8M | -$5.1M | -$8.3M |
| Net margin | −1590.4% | −1967.7% | −140.8% | −157505.1% | 18970.7% | −17219.1% | — | −11279.4% | 57539.2% | −72622.6% | −279.8% | −829.9% |
| Diluted EPS | $-0.20 | $-0.21 | $-0.10 | $-0.28 | $-0.45 | $-0.50 | — | $-0.55 | $1.52 | $-0.81 | $-0.24 | $-1.09 |
| EBITDA | -$2.4M | -$2.4M | -$936.9K | -$3.2M | -$3.4M | -$4.4M | $6.4K | -$4.7M | -$7.3M | -$6.0M | -$5.2M | -$8.4M |
| Operating cash flow | -$6.8M | -$5.5M | $1.4M | -$442.1K | -$5.4M | -$5.5M | $5.3M | -$5.9M | $12.9M | -$6.8M | -$8.2M | -$8.0M |
| Free cash flow | -$6.9M | -$5.5M | $1.2M | -$616.8K | -$5.6M | -$5.6M | $4.7M | -$6.2M | $12.6M | -$6.8M | -$8.8M | -$8.0M |
| Diluted shares | 14.9M | 14.5M | 14.3M | 12.8M | 8.9M | 8.8M | 8.6M | 8.5M | 8.5M | 8.4M | 20.7M | 7.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.6M | $18.5M | $24.7M | $23.1M | $5.0M | $10.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $161.5K | $597.6K | $1.5M | $2.0M | $2.2M | $2.5M |
| Total assets | $22.4M | $27.8M | $32.5M | $30.7M | $13.0M | $18.6M |
| Total liabilities | $22.9M | $27.1M | $29.6M | $27.9M | $25.7M | $28.2M |
| Shareholders' equity | -$560.1K | $734.5K | $2.8M | $2.9M | -$12.7M | -$9.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology